A randomized comparison of nifedipine and ritodrine for suppression of preterm labor.
OBJECTIVE
To compare the efficacy and safety of nifedipine and ritodrine in preventing preterm labor, and to evaluate maternal side effects and neonatal outcome.


METHODS
Non-blind, randomized controlled trial


RESULTS
A randomized trial of 102 pregnant women with gestational ages under 34 weeks, including 24 with twin pregnancies and 45 on betasympathicomimetic drugs, who had regular uterine contractions with either observed cervical changes or preterm rupture of membranes. After stratification women were randomly assigned to receive either ritodrine intravenously or nifedipine orally. Fifty-five women were randomized to the nifedipine group and 47 to the ritodrine group. As expected, both groups were comparable in terms of several entry variables, including mean gestational age, ruptured membranes, treatment with tocolytic drugs, cervical examination, contraction frequency, age, and twin gestation. Delivery of women in the nifedipine group was delayed for 48 h, 7 days, and until 34 weeks gestation in 33 (60%), 26 (47%) and 21(38%) cases, respectively, compared with 31 (66%), 21(45%) and 11(23%) women in the ritodrine group (no significant difference). Maternal side effects were significantly less common in the nifedipine group than in the ritodrine group, however after 7 days of therapy there was no difference between the two groups. Neonatal outcome was similar in the two groups, with four neonatal deaths in the nifedipine and five in the ritodrine group.


CONCLUSIONS
Nifedipine seems to be as effective as ritodrine in the treatment of preterm labor and is associated with less frequent side effects.
Koks
C A
CA
Department of Obstetrics and Gynecology, Academic Hospital of Maastricht, The Netherlands.
Brölmann
H A
HA
de Kleine
M J
MJ
Manger
P A
PA
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D005865:Gestational Age; D006801:Humans; D009543:Nifedipine / Q000009:adverse effects / Q000627:therapeutic use*; D007752:Obstetric Labor, Premature / Q000517:prevention & control*; D011188:Potassium / Q000097:blood; D011247:Pregnancy; D011256:Pregnancy Outcome; D011272:Pregnancy, Multiple; D012312:Ritodrine / Q000009:adverse effects / Q000627:therapeutic use*; D015149:Tocolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014427:Twins
D001786:Blood Glucose; D015149:Tocolytic Agents; D012312:Ritodrine; D009543:Nifedipine; D011188:Potassium